HEGGIE THERESA 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Aug 15, 2025
Insider Transaction Report
Form 4
HEGGIE THERESA
Director
Transactions
- Exercise/Conversion
Common Stock
2025-08-13$2.91/sh+30,000$87,300→ 95,352 total - Exercise/Conversion
Automatic Stock Option Grant
2025-08-13−40,000→ 0 totalExercise: $5.41From: 2021-05-12Exp: 2030-05-12→ Common Stock (40,000 underlying) - Exercise/Conversion
Common Stock
2025-08-13$5.41/sh+40,000$216,400→ 135,352 total - Sale
Common Stock
2025-08-13$8.51/sh−70,000$595,868→ 65,352 total - Exercise/Conversion
Automatic Stock Option Grant
2025-08-13−30,000→ 0 totalExercise: $2.91From: 2020-05-29Exp: 2029-05-29→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.48 to $8.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.